The effect of nimodipine, fentanyl and remifentanil intravenous products on the stability of propofol emulsions
Nimodipine is used parenterally to treat ischemic neurological deficits caused by subarachnoid haemorraghe. Infusion of nimodipine should be continued during anaesthesia, surgery or angiography. In this context a simultaneous administration of nimodipine, propofol and fentanyl or remifentanil
could be of great advantage. So the aim of this study was to evaluate the physical stability (droplet size) of propofol emulsions in combination with nimodipine and fentanyl/remifentanil. Droplet size of intravenous emulsions is of particular relevance as the administration of larger droplets
to patients may cause pulmonary embolism. So the number of oil droplets >10 μm was determined in combinations of propofol emulsion with nimodipine and fentanyl/remifentanil immediately after mixing and after 20 hours by using microscopy. The experiments showed that all combinations of
propofol (1 and 2%) with nimodipine infusion solution resulted in coalescence of oil droplets, which finally caused a visible phase separation. Macrogol (polyethylene glycol 400) was identified as the component in nimodipine infusion solution which induced the physicochemical incompatibility
with propofol lipid emulsions.
No References for this article.
No Supplementary Data.
No Article Media
Document Type: Research Article
Hospital Pharmacy Department, SMZ-Ost/Donauspital Wien, Vienna, Austria
Institute of Pharmaceutical Sciences, Karl-Franzens-University, Graz, Austria
Department of Pharmaceutical Technology, Institute of Pharmacy, University of Leipzig, Leipzig, Germany
Institute of Pharmaceutical Sciences, University of Graz, Schubertstraße 1, Graz, 8010, Austria, Email: [email protected]
February 1, 2009
More about this publication?
Pharmazie is a leading journal in the field of pharmaceutical sciences. As a peer-reviewed scientific journal, Pharmazie is regularly indexed in the relevant databases like Web of science, Journal Citation Reports and many others. The journal is open for submissions from the whole spectrum of pharnaceutical sciences including Pharmaceutical Chemistry, Experimental and Clinical Pharmacology, Drug Analysis, Pharmaceutics, Pharmaceutical Biology, Clinical Pharmacy etc.
- Information for Authors
- Submit a Paper
- Subscribe to this Title
- Ingenta Connect is not responsible for the content or availability of external websites